Medstar Georgetown University Hospital
Welcome,         Profile    Billing    Logout  
 54 Trials 
85 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Paul R
NCT03102125: Allograft Dysfunction in Heart Transplant

Recruiting
4
376
US
Regadenoson, Lexiscan
Paul Kim
Heart Transplant Failure and Rejection
12/24
12/24
PE-TRACT, NCT05591118: Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Recruiting
3
500
US
Anticoagulant Therapy, Catheter-Directed Therapy
NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Embolism
01/27
01/28
NCT05417074: Assessing SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Not yet recruiting
2
10
US
Placebo, SLS-002, Intranasal Racemic Ketamine, Standard of care
Johns Hopkins University, Seelos Therapeutics, Inc.
Depression, Suicidal Behavior, Suicidal Ideation
03/23
08/23
ELIMINATE, NCT05488340: A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli ( Trial)

Recruiting
2
318
US
LBP-EC01 0.1 x IV dose, 1x10^11 PFU IV dose, LBP-EC01 0.01x IV Dose, 1x10^10 PFU IV Dose, LBP-EC01 IV Infusion Dose, 1x10^12 PFU IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Locus Biosciences, Parexel
Urinary Tract Infections
06/25
12/25
NCT03543007: Evaluating the Safety and Efficacy of GrafixPL™PRIME for the Treatment of Chronic Venous Leg Ulcers

Not yet recruiting
N/A
30
US
GrafixPL™ PRIME plus standard compression therapy, standard compression therapy alone
Georgetown University, Osiris Therapeutics
Venous Leg Ulcer, Chronic Leg Ulcer, Venous Insufficiency, Venous Stasis
09/22
01/23
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
NCT04684901: Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF Procedures

Enrolling by invitation
N/A
50
US
AlloWrap® Amniotic Membrane
AlloSource
Cervical Stenosis, Spondylolisthesis, Cervical Radiculopathy, Cervical Disc Disorder
06/25
01/26
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Not yet recruiting
N/A
250
US
The Prospera™ Test
Natera, Inc.
Heart Transplant Failure and Rejection
12/24
12/25
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

Active, not recruiting
N/A
147
US
Prospera
Natera, Inc.
Heart Transplant
12/24
12/24
NCT01420237: Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study

Active, not recruiting
N/A
352
Europe, Canada, US
Restoration ADM X3 Device
Stryker Orthopaedics
Arthroplasty, Replacement, Hip
06/26
06/26
Cheson, Bruce D
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
02/25
08/28
NCT02758717: Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Checkmark From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
Dec 2019 - Dec 2019: From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
Checkmark Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019
Dec 2019 - Dec 2019: Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019
Active, not recruiting
2
46
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
08/19
05/24
NCT04545333: The clonoSEQ® Watch Registry

Active, not recruiting
N/A
528
US
clonoSEQ Assay
Adaptive Biotechnologies
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
12/24
12/24
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26
He, Aiwu R
NCT04306367: Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Active, not recruiting
2
13
US
Pembrolizumab, Keytruda, Olaparib, LYNPARZA
Georgetown University
Cholangiocarcinoma
12/22
12/23
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated
2
6
US
Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin
Aiwu Ruth He, MD, Georgetown University, Genentech, Inc.
Hepatocellular Carcinoma
06/23
06/23
ESR-22-21719, NCT06017297: Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Recruiting
2
28
US
Durvalumab, Tremelimumab, Gemcitabine, Cisplatin, Surgical Resection
Georgetown University, AstraZeneca
Borderline Resectable Carcinoma, Biliary Tract Cancer
11/26
11/26
ROWAN, NCT05063565: TheraSphere With Durvalumab and Tremelimumab for HCC

Recruiting
2
100
Europe, US
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Boston Scientific Corporation, Biocompatibles UK Ltd
Hepatocellular Carcinoma
06/27
06/27
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
1/2
166
US
TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin®
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
03/25
03/25
NCT03278925: Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

Active, not recruiting
1
14
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pharmacological Study, Questionnaire Administration, Ultrasound
National Cancer Institute (NCI)
Cirrhosis
06/23
12/24
Collins, Sean P
DICTATE-AHF, NCT04298229: Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Completed
3
240
US
Dapagliflozin 10 MG, sodium-glucose cotransporter-2(SGLT2) inhibitors, Protocolized Diuretic Therapy
Vanderbilt University Medical Center, AstraZeneca
Heart Failure, Diabetes Mellitus, Type 2
05/23
05/23
NECTAR, NCT04924660: Novel Experimental COVID-19 Therapies Affecting Host Response

Completed
2/3
871
US
TXA127, TRV027, Placebo, Fostamatinib
Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
10/23
12/23
NCT01618851: Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer

Active, not recruiting
2
70
NA
Radiotherapy with IMRT and CyberKnife Boost
Georgetown University
Prostate Cancer
02/25
02/25
NCT04481919: Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Recruiting
2
474
US
Protocolized diuretic therapy
Vanderbilt University Medical Center
Heart Failure, Acute Heart Failure
09/26
12/26
NCT05410366: Safe Harbors in Emergency Medicine, Specific Aim 3

Withdrawn
N/A
2300
US
Safe harbor clinical practice guideline
Vanderbilt University Medical Center, Agency for Healthcare Research and Quality (AHRQ)
Low Back Pain, Headache, Head Injury, Minor
03/24
03/24
NCT06415058: Study to Investigate Blood Samples Drawn With the HemoIV System

Enrolling by invitation
N/A
106
US
HemoIV
Vanderbilt University Medical Center, MedTG LLC
Measurement of Blood Parameter Equivalency
11/24
06/25
NCT06400602: Health Coaching for Back Pain After Emergency Department Discharge

Recruiting
N/A
40
US
Usual ED Care plus Health Coaching, Usual ED Care plus Education
Vanderbilt University Medical Center
Low Back Pain
09/25
09/25
NCT01968538: Metabolomic Study for Localized Prostate Cancer

Enrolling by invitation
N/A
400
US
Radiation Therapy, Prostate stereotactic body radiation therapy (SBRT) and intensive modulated radiation therapy (IMRT) or the combination of both (boost)
Georgetown University
Prostate Cancer
12/24
12/24
PR-PROS, NCT01766492: Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery

Recruiting
N/A
200
US
Stereotactic Body Radiation Therapy (SBRT), CyberKnife radiosurgery
Georgetown University
Prostate Cancer, Localized Malignant Neoplasm
04/25
04/25
Cooper, Matthew
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry

Recruiting
N/A
5000
US
Prospera
Natera, Inc., University of Maryland
Kidney Transplant Rejection
10/26
10/27
Pishvaian, Michael J
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting
3
320
Europe, US
Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath, RenovoCath RC120
RenovoRx
Locally Advanced Pancreatic Cancer
09/22
09/23
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
NCT02249949: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

Completed
2
15
US
efatutazone
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Daiichi Sankyo, Inc.
Liposarcoma
10/18
05/23
NCT04390243: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Terminated
2
6
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
11/23
11/23
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
SWOG S2001, NCT04548752: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Recruiting
2
88
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475
National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
03/25
03/25
NCI-2020-05659, NCT04858334: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Recruiting
2
152
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Placebo Administration
National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
10/27
10/27
NCT03376659: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Checkmark Study of CV301 + durvalumab in CRC & pancreatic cancer
Nov 2018 - Nov 2018: Study of CV301 + durvalumab in CRC & pancreatic cancer
Terminated
1/2
8
US
Durvalumab, MEDI4736, CV301, Capecitabine, Xeloda, Bevacizumab, Avastin
Georgetown University, Mayo Clinic, Indiana University, Emory University, National Cancer Institute (NCI), George Mason University, Thomas Jefferson University, MedImmune LLC, Bavarian Nordic
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
08/21
08/23
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
ETCTN 10366, NCT04172532: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer

Recruiting
1/2
98
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib, Placebo Administration
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
08/24
08/24
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Terminated
1
23
US
Niraparib, MK-4827, Carboplatin, Paraplatin
Georgetown University, Tesaro, Inc., Oregon Health and Science University
Solid Tumor, Adult, Homologous Recombination Deficiency
10/23
10/23
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
Ujjani, Chaitra
NCT04419519: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Recruiting
2
80
US
Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
Memorial Sloan Kettering Cancer Center, Adaptive Biotechnologies
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
05/25
05/25
NCT02956382: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Active, not recruiting
1/2
24
US
Ibrutinib, PCI-32765, Venetoclax, ABT-199
Georgetown University, AbbVie, Pharmacyclics LLC., Hackensack Meridian Health
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
05/23
11/24
NCT01829568: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Active, not recruiting
1
33
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Pharmacological Study, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI), Celgene Corporation
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
05/15
01/25
NCT04852822: Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
N/A
345
US
Biospecimen Collection, Electronic Health Record Review
University of Washington, CLL Global Research Foundation
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
01/23
07/24
Kim, Alexander
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
Lynce, Filipa
NCT01796197: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Active, not recruiting
2
23
US
Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
Dana-Farber Cancer Institute
Breast Cancer
06/18
07/24
NCT02623972: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Active, not recruiting
2
22
US
Eribulin, Halaven, B1939 mesylate, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan®, Neosar®
Dana-Farber Cancer Institute, Eisai Inc.
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
05/21
12/26
NCT02876302: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Active, not recruiting
2
23
US
Ruxolitinib, Jakafi, Paclitaxel, Taxol, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan
Dana-Farber Cancer Institute, Incyte Corporation
Inflammatory Breast Cancer (IBC)
12/22
08/24
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TRUDI, NCT05795101: TDXD+Durva in HER2+/Low IBC

Recruiting
2
63
US
Trastuzumab deruxtecan, Enhertu, Durvalumab
Filipa Lynce, MD, AstraZeneca, Daiichi Sankyo, Inc.
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
12/27
12/32
NCT03345485: Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

Completed
1/2
71
Canada, US
Tinostamustine (EDO-S101)
Mundipharma Research Limited
Small-cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
ZAP-IT, NCT06351332: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Recruiting
1/2
78
US
Azenosertib, ZN-c3, KP-2638, Carboplatin, C6H12N2O4Pt, platinum, diammine[1,1-cyclobutanedicarboxylato(2-)- O,O']-, (SP-4-2), Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1-mAB (H409A11) IgG4, C6504H10004N1716O2036S46
Filipa Lynce, MD, Merck Sharp & Dohme LLC, Zentalis Pharmaceuticals
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
03/27
09/29
NCT03641755: Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Active, not recruiting
1
10
US
Sapacitabine, CYC682, Olaparib, Lynparza
Dana-Farber Cancer Institute, AstraZeneca, Cyclacel Pharmaceuticals, Inc.
Breast Cancer
04/22
06/25
Salem, Mohamed
NCT05807711: Efficacy of L-methylfolate and Methylcobalamine in Treating Hypertension and Its Impact on Serum Homocysteine in Hemodialysis Patients With Resistant Hypertension

Active, not recruiting
4
51
RoW
L-Methyl Folate and methylcobalamine
Alexandria University
End Stage Renal Disease, Hypertension, Renal
05/24
05/24
EA2176, NCT04444921: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Recruiting
3
205
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Anal Basaloid Squamous Cell Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma
03/26
03/26
NCT05838846: Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery

Active, not recruiting
2/3
116
RoW
Inhaled Milrinone, IV Milrinone
Menoufia University
Mitral Valve Replacement, Pulmonary Hypertension, Inhaled Milrinone, Intravenous Milrinone
10/24
03/25
COBRA, NCT04068103: Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Active, not recruiting
2/3
1408
Canada, US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting
NRG Oncology, National Cancer Institute (NCI)
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
04/25
04/27
SWOG S1922, NCT04205968: Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Recruiting
2
94
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
06/25
06/25
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
NCT05367869: Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy

Not yet recruiting
N/A
40
NA
Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy
Qena Oncology Center
Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy
05/23
05/23
NCT06116370: The Clinical Efficacy of Rezūm Therapy Versus Bipolar Trans-urethral Resection of the Prostate for Treatment Benign Prostatic Hyperplasia

Completed
N/A
100
RoW
Rezum procedure, B-TURP procedure
Ain Shams University
Prostatic Hyperplasia
06/23
09/23
NCT06031103: Clinical Efficacy of Mini-PCNLversus RIRS for the Management of Upper Urinary Tract Calculus (1-2.5 cm)

Completed
N/A
60
RoW
mini-PCNL procedure, RIRS procedure
Ain Shams University
Stone, Kidney
07/23
08/23
ACCESS, NCT04602611: Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers

Completed
N/A
240
US
Oncology Nurse Navigation
Wake Forest University Health Sciences
Gastrointestinal Cancer
08/23
08/23
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting
N/A
750
Canada, US
MRD
Exact Sciences Corporation, NSABP Foundation Inc
Colorectal Cancer
02/28
02/28
Willey, Shawna C
NCT01570998: Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Recruiting
N/A
1500
US
Intraoperative Radiation Therapy, Intraoperative Radiotherapy, IORT, radiotherapy, intraoperative, Laboratory Biomarker Analysis
University of California, San Francisco, Carl Zeiss Meditec AG
Stage IA Breast Cancer, Stage IIA Breast Cancer
12/27
12/27
Kim, Sunnie
SWOG S2001, NCT04548752: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Recruiting
2
88
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475
National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
03/25
03/25
MK3475-A53, NCT05379972: Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Recruiting
2
26
US
Pembrolizumab, Keytruda, Olaparib, Lynparza, Stereotactic Body Radiation Therapy, SBRT
University of Colorado, Denver, Merck Sharp & Dohme LLC
Gastric Cancer, GastroEsophageal Cancer
12/25
12/28
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
INCLINE-101, NCT05399654: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
200
US, RoW
TAC-001
Tallac Therapeutics
Advanced or Metastatic Solid Tumors
01/26
05/26
NCT05121948: A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Terminated
1
35
US
HC-7366
HiberCell, Inc., Covance
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
02/24
03/24
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
Broome, Catherine M
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Recruiting
3
50
Europe, Japan, US, RoW
Iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
Atypical Hemolytic Uremic Syndrome
12/25
01/26
NCT05002777 / 2021-001671-16: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Active, not recruiting
2
22
Europe, US, RoW
rilzabrutinib, PRN1008/SAR444671
Sanofi, Sanofi Aventis Recherche et Developpement
Warm Autoimmune Hemolytic Anemia (wAIHA)
05/24
05/25
TPO-RA, NCT05885555: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Recruiting
2
40
Europe, US, RoW
Ianalumab, VAY736
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
03/27
03/29
NCT06291415: The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Recruiting
1
48
Europe, US, RoW
HMPL-523
Hutchmed
Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
04/26
11/26
Gilbert, Alexander
NCT02602262: Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients

Recruiting
N/A
125
US
HIV-infected deceased donor organ
Johns Hopkins University, University of Colorado, Denver, Yale University, Georgetown University, Emory University, Rush University Medical Center, University of Illinois at Chicago, Indiana University, University of Maryland, Columbia University, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Pittsburgh Medical Center, Methodist Health System, Northwestern University, NYU Langone Health, University of Virginia, Washington University School of Medicine, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
07/25
07/26
NCT04910867: APOL1 Genetic Testing Program for Living Donors

Recruiting
N/A
390
US
Components of Genetic Counseling, APOL1 genetic testing, EHR integration
Northwestern University, Georgetown University
Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
05/25
07/25
Novielli, Nellie
WI223281, NCT03535506: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

Terminated
2
17
US
Palbociclib, Ibrance
Georgetown University, Pfizer
DCIS
12/23
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27

Download Options